The work that you do here everyday is generating more information about the human genome. That information is going to flow out of Millennium in one way or another and eventually make its way into clinical medicine and affect our lives. There are some very large social questions that we are in a position to help educate the public about and generate some answers about. It is a hugely exciting time, but excitement doesn't always mean good. Exciting can mean it's also there are difficult issues.
Millennium is one of a dozen or so genomic companies that have sprung up over the last three years.
Millennium approached me and said, what about engaging a dialogue with our scientists asking them some tough questions. I said sure. I mean, whether it's atherosclerosis or obesity or diabetes or asthma, I mean, these are huge markets, too, when you think about it. Schizophrenia, I think and manic depression are 13 million people. I mean, these are huge diseases.